Ulisse Biomed SpA (MIL:UBM) ROCE % : -22.20% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ulisse Biomed SpA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ulisse Biomed SpA's annualized ROCE % for the quarter that ended in Jun. 2024 was -22.20%.

Ulisse Biomed SpA ROCE % Historical Data

The historical data trend for Ulisse Biomed SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ulisse Biomed SpA ROCE % Chart

Ulisse Biomed SpA Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-73.15

19.10

-13.66

-19.79

-13.86

Ulisse Biomed SpA Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial					-14.18	-22.64	-119.99	9.84	-22.20

Ulisse Biomed SpA ROCE % Calculation

Ulisse Biomed SpA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.472	/	( ( (6.574 - 0.611)	+	(31.177 - 1.477) )	/ 2 )
	=	-2.472	/	( (5.963	+	29.7)	/ 2 )
	=	-2.472	/	17.8315
	=	-13.86 %

Ulisse Biomed SpA's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-6.108	/	( ( (31.177 - 1.477)	+	(28.585 - 3.267) )	/ 2 )
	=	-6.108	/	( ( 29.7	+	25.318 )	/ 2 )
	=	-6.108	/	27.509
	=	-22.20 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Ulisse Biomed SpA (MIL:UBM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ulisse Biomed SpA ROCE % Related Terms

Thank you for viewing the detailed overview of Ulisse Biomed SpA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ulisse Biomed SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ulisse Biomed SpA (MIL:UBM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Area Science Park - SS14 km.163, 5, Basovizza, ITA, 34149

Website

https://www.ulissebiomed.com

Ulisse Biomed SpA is a healthcare biotech company. It is engaged in developing medical diagnostics, theranostics, and therapeutics solutions. The company has three technology platforms, namely, Sagitta for molecular diagnostics, NanoHybrid for theranostics and diagnostics, and Aptavir for therapeutics.

Ulisse Biomed SpA Headlines

No Headlines